WST Raises 2026 Outlook on Biologics Surge

West Pharmaceutical Services lifts full-year guidance after Q2 revenue climbs 13% organically to $872 million, driven by 29% biologics growth and GLP-1 momentum.

Q2 adjusted EPS of $2.37 beat consensus by $0.29; full-year EPS guidance raised to $8.85–$9.05.
Biologics market group delivered 29% organic growth; High-Value Products now represent 49% of revenue.
WST stock gained nearly 8% in premarket trading following the July 23 earnings release.

Lead

West Pharmaceutical Services (NYSE: WST) raised its full-year 2026 revenue and earnings guidance on July 23, after second-quarter results came in well ahead of Wall Street expectations. The Exton, Pennsylvania–based drug delivery technology company posted quarterly net sales of $872 million, a 13.8% year-over-year increase and organic growth of 12.7%, powered by surging biologics demand and accelerating adoption of its high-value product components. Adjusted earnings per share of $2.37 exceeded the consensus estimate of $2.08 by $0.29. Chief Executive Eric Green called the performance a reflection of a durable, multi-year demand cycle across biologics, GLP-1 therapies, and regulatory-driven containment upgrades.

What Happened

West's Proprietary Products segment—the company's highest-margin division—generated $872.3 million in total revenue, with the segment alone contributing $722.6 million, up 16.6% from a year earlier. Within that segment, High-Value Product (HVP) Components sales rose 19.4% to $424.1 million, as pharmaceutical and biotech customers shifted toward premium containment systems for injectable medicines.

The biologics market group was the standout performer, posting 29% organic growth in the quarter. Green attributed the acceleration to expanding biosimilar pipelines, rising clinical-stage volumes for large-molecule therapies, and a structural preference among drug manufacturers for West's more complex, contamination-resistant components. GLP-1-related HVP components also showed sustained strength, with management projecting high-teens organic growth in that category for the full year, supported by Medicare expansion and global generic GLP-1 rollouts.

HVP components now constitute 49% of total company revenue, up from prior-year levels, reflecting a deliberate portfolio shift that is simultaneously lifting margins. Operating margin expanded by more than 200 basis points in the quarter, aided by favorable product mix, pricing gains, and volume leverage.

Market Reaction

WST stock climbed roughly 8% in premarket trading on July 24 to approximately $387 per share, building on a year marked by investor re-rating of the company's exposure to biologics and GLP-1 infrastructure. The move reflected not only the earnings beat but also the magnitude of the guidance lift—a signal that management views demand conditions as more than transitory.

Strategic Context

West's raised full-year 2026 revenue guidance of $3.345 billion to $3.38 billion compares with a prior range of $3.29 billion to $3.35 billion and sits slightly above the Wall Street consensus of $3.332 billion. Full-year adjusted EPS guidance moved to $8.85–$9.05, up from the prior range of $8.40–$8.75. For the third quarter, West guided for revenue of $820 million to $835 million.

A second structural tailwind is the ongoing compliance transition under Annex 1, the European Union's revised good manufacturing practice regulation for sterile medicinal products. Green said Annex 1–related upgrade projects are on track to contribute 200 basis points of revenue growth in 2026. The company currently holds just under 800 active Annex 1 and HVP upgrade projects, a figure management said is up 50% from the same period a year ago, suggesting the conversion pipeline remains deep.

To support capacity, West expanded its Dublin manufacturing facility in late March 2026 for high-volume injectable therapies, and in April 2026 commissioned additional capacity at its Jurong, Singapore site to serve Asia-Pacific biologics demand.

The company also completed the divestiture of its SmartDose 3.5mL drug delivery device business on July 1, 2026, a move expected to reduce revenue dilution and further improve the consolidated margin profile in the second half of the year. A $1 billion share repurchase authorization further underscores management's confidence in the earnings trajectory.

What Comes Next

West enters the second half of 2026 with a backlog of Annex 1 upgrade projects, rising biologics program wins, and growing GLP-1 component orders. The broader pharmaceutical contract manufacturing market—encompassing biologics and injectable therapies—is forecast to expand from roughly $210 billion in 2025 to $312 billion by 2030, a compound annual growth rate of approximately 8.2%, providing a long-duration demand backdrop for West's specialized containment and delivery systems.

Outlook

West Pharmaceutical's second-quarter results reinforce its position as a primary infrastructure supplier to the biologics and GLP-1 drug delivery ecosystem. With HVP components approaching half of total revenue, a 50% year-over-year rise in regulatory-upgrade projects, and guidance raised meaningfully above prior consensus, the company has signaled that the demand environment remains broad-based and durable. Full-year 2026 adjusted EPS of $8.85–$9.05 implies continued margin expansion through the second half as the SmartDose divestiture clears the portfolio.

Mentioned tickers: WST

Earnings }}